Skip to content

A Prospective Multicenter Clinical Observation Study OF target concentration of vancomycin in Chinese patients

A Prospective Multicenter Clinical Observation Study OF target concentration of vancomycin in Chinese patients

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OPC-17012567
Enrollment
Unknown
Registered
2017-09-04
Start date
2019-04-30
Completion date
Unknown
Last updated
2017-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gram Positive Bacteria Infection

Interventions

Sponsors

Huashan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients have been diagnosed as gram-positive infections and treated by vancomycin In accordance with the following requirements: 1. Unlimited gender, age and weight; 2. Confirm the patients of gram-positive infections by clinical symptoms, signs, laboratory and pathogenic microorganism examination, such as bloodstream infection, pulmonary infection, abdominal cavity infection, central nervous system infection, skin and soft tissue infection, urinary tract infection; 3. Received vancomycin>5 days; Selected patients:Bloodstream infection, pulmonary infection (except coagulase negative staphylococcus), abdominal cavity infection, central nervous system infection,skin and soft tissue infection (except coagulase negative staphylococcus), urinary tract infection caused by Staphylococcus aureus, Enterococcus, Streptococcus; 4. Require the use of vancomycin; 5. Allergic patients to ß-lactam antibiotics such as penicillin and cephalosporin can also be selected; 6. Patients with informed consent.

Exclusion criteria

Exclusion criteria: 1. Any patient conforms to the following items is not the object of investigation; 2. Patients effectively treated by anti-gram-positive agents within 72 hours before being selected, such as norvancomycin,teicoplanin, linezolid, and fusidic acid, compound SMZ/TMP,tigecycline and daptomycin; 3. Patients with colonized gram positive cocci or not infected; 4. Vancomycin treatment within 5 days (Except hemodialysis and peritoneal dialysis patients); 5. Pregnancy or breastfeeding women; 6. Patients combined with aminoglycosides; 7. Patients lacking of clinical infection and laboratory evaluation index and could not be evaluated the clinical efficacy and safety; 8. Participat in other clinical trials within 1 months.

Design outcomes

Primary

MeasureTime frame
effecacy and safety;

Countries

China

Contacts

Public ContactJing Zhang, Jufang Wu

Huashan Hospital, Fudan University

zhangj_fudan@163.com+86 021-52888190

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026